See more : Atsugi Co., Ltd. (3529.T) Income Statement Analysis – Financial Results
Complete financial analysis of Scinai Immunotherapeutics Ltd. (SCNI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scinai Immunotherapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kanematsu Electronics Ltd. (KSUEF) Income Statement Analysis – Financial Results
- Manz AG (MANZF) Income Statement Analysis – Financial Results
- Equinox Resources Limited (EQN.AX) Income Statement Analysis – Financial Results
- Citrix Systems, Inc. (0HYR.L) Income Statement Analysis – Financial Results
- Tekkorp Digital Acquisition Corp. (TEKK) Income Statement Analysis – Financial Results
Scinai Immunotherapeutics Ltd. (SCNI)
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 167.98K | 76.22K | 66.96K | 73.42K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -167.98K | -76.22K | -66.96K | -73.42K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.21M | 5.77M | 3.25M | 16.01M | 19.88M | 19.27M | 5.58M | 2.44M | 2.76M | 1.65M | 1.94M | 1.61M | 1.53M | 1.80M | 805.34K | 882.39K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.51M | 5.30M | 7.63M | 5.19M | 2.81M | 1.38M | 1.40M | 1.07M | 871.81K | 680.13K | 631.56K | 574.69K | 602.75K | 668.83K | 299.68K | 343.07K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -23.49M | 1.00 | -38.24K | -185.65K | -416.06K | -726.29K | -243.56K | -366.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.72M | 11.06M | 10.87M | -2.28M | 22.69M | 20.61M | 6.80M | 3.09M | 2.90M | 2.09M | 2.20M | 2.19M | 2.13M | 2.47M | 1.11M | 1.23M |
| Cost & Expenses | 9.72M | 11.06M | 10.87M | -2.28M | 22.69M | 20.61M | 6.80M | 3.09M | 2.90M | 2.09M | 2.20M | 2.38M | 2.30M | 2.54M | 1.17M | 1.30M |
| Interest Income | 122.68K | 8.10M | 928.76 | -9.71K | 8.30K | 1.35M | 5.04K | 14.38K | 2.83K | 21.19K | 37.80K | 65.04K | 129.34K | 85.62K | 8.66K | 89.89K |
| Interest Expense | -317.00 | 5.05M | -3.15M | 338.76K | 4.28M | 3.78M | -129.95 | 100.00 | 7.80 | 1.69K | -1.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 514.00K | 562.00K | 471.00K | 468.56K | 461.69K | 69.53K | 123.55K | 162.32K | 161.62K | 173.75K | 204.46K | 190.18K | 167.98K | 76.22K | 66.96K | 73.42K |
| EBITDA | -9.19M | -10.50M | -10.39M | 2.75M | -22.21M | -20.54M | -6.67M | -2.93M | -2.74M | -1.92M | -2.00M | -2.24M | -1.99M | -2.41M | -1.10M | -1.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.72M | -11.06M | -10.87M | 2.28M | -22.69M | -20.61M | -6.80M | -3.09M | -2.90M | -2.09M | -2.20M | -2.38M | -2.30M | -2.54M | -1.17M | -1.30M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.22M | 5.27M | 2.67M | -3.67M | -8.93M | -2.85M | -3.13M | 704.94K | 283.33K | 97.02K | -113.91K | -51.25K | 142.22K | 53.68K | 6.87K | 88.21K |
| Income Before Tax | -6.50M | -5.80M | -8.21M | -1.39M | -31.62M | -23.46M | -9.93M | -2.38M | -2.62M | -1.99M | -2.32M | -2.43M | -2.16M | -2.49M | -1.17M | -1.21M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -6.50M | -5.80M | -8.21M | -1.39M | -31.62M | -23.46M | -9.93M | -2.38M | -2.62M | -1.99M | -2.32M | -2.43M | -2.16M | -2.49M | -1.17M | -1.21M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.64 | -30.74 | -58.14 | -12.51 | -387.21 | -358.95 | -197.58 | -70.58 | -99.22 | -146.80 | -193.35 | -230.45 | -223.97 | -279.13 | -173.14 | -189.82 |
| EPS Diluted | -16.64 | -30.74 | -58.14 | -12.51 | -387.21 | -358.95 | -197.58 | -70.58 | -99.22 | -146.80 | -193.33 | -230.45 | -223.97 | -279.13 | 0.00 | -189.82 |
| Weighted Avg Shares Out | 390.66K | 188.52K | 141.14K | 110.81K | 81.66K | 65.35K | 50.26K | 33.77K | 26.38K | 13.57K | 11.99K | 10.53K | 9.65K | 8.91K | 6.73K | 6.38K |
| Weighted Avg Shares Out (Dil) | 390.66K | 188.52K | 141.14K | 110.82K | 81.66K | 65.36K | 50.26K | 33.77K | 26.38K | 13.57K | 11.99K | 10.53K | 9.65K | 8.91K | 0.00 | 6.38K |
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
JERUSALEM , Dec. 5, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in the development of inflammation and immunology (I&I) biological products and offering CDMO services through its Scinai Bioservices unit, announced...
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board
JERUSALEM , Nov. 27, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced today...
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
JERUSALEM , Nov. 22, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published...
Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024
JERUSALEM , Oct. 31, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices unit, today announced that it will be showcasing its innovative I&I...
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
JERUSALEM, Israel , Sept. 16, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.
LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part...
Scinai Regains Full Compliance with Nasdaq Listing Requirements
JERUSALEM , Aug. 29, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced...
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
JERUSALEM , Aug. 21, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI; "Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today...
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI ) Q2 2024 Results Conference Call August 20, 2024 11:00 AM ET Company Participants Liat Halpert - Head of Business Development Amir Reichman - CEO Liat Halpert Good morning, everyone.
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
JERUSALEM , Aug. 20, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that...
Source: https://incomestatements.info
Category: Stock Reports